[go: up one dir, main page]

CA2167920A1 - Nanoparticules et microparticules de copolymeres multisequences, hydrophiles-hydrophobes, non lineaires - Google Patents

Nanoparticules et microparticules de copolymeres multisequences, hydrophiles-hydrophobes, non lineaires

Info

Publication number
CA2167920A1
CA2167920A1 CA002167920A CA2167920A CA2167920A1 CA 2167920 A1 CA2167920 A1 CA 2167920A1 CA 002167920 A CA002167920 A CA 002167920A CA 2167920 A CA2167920 A CA 2167920A CA 2167920 A1 CA2167920 A1 CA 2167920A1
Authority
CA
Canada
Prior art keywords
acid
particle
group
polymer
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002167920A
Other languages
English (en)
Inventor
Abraham J. Domb
Ruxandra Gref
Yoshiharu Minamitake
Maria Teresa Peracchia
Robert S. Langer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/096,370 external-priority patent/US5543158A/en
Priority claimed from US08/210,677 external-priority patent/US5565215A/en
Application filed by Individual filed Critical Individual
Publication of CA2167920A1 publication Critical patent/CA2167920A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Acoustics & Sound (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

L'invention concerne des particules qui ne sont pas supprimées rapidement de la circulation sanguine par les macrophages du système réticuloendothélial et qui peuvent être modifiées, afin de réaliser des fréquences variables de libération ou de cibler des cellules ou des organes spécifiques. Les particules possèdent un noyau d'un copolymère multibloc constitué par liaison covalente d'un composé multifonctionnel avec un ou plusieurs polymères hydrophobes et un ou plusieurs polymères hydrophiles et contiennent un matériau biologiquement actif. Le groupe hydroxyle terminal du polyalkyline glycol peut s'utiliser, afin d'effectuer la fixation covalente de molécules biologiquement actives sur la surface des particules, y compris des anticorps ciblés vers des cellules ou des organes spécifiques ou des molécules exerçant un effet sur la charge, le caractère lipophile ou hydrophile de la particule. La surface de la particule peut également être modifiée par fixation de polymères biodégradables présentant la même structure que ceux qui constituent le noyau des particules. La dimension typique des particules se situe entre 180 nm et 10.000 nm, de préférence entre 180 nm et 240 nm, bien que des particules peuvent également présenter la constitution décrite ci-dessus. Les particules peuvent comprendre des particules magnétiques ou des matériaux radioopaques s'utilisant en imagerie diagnostique, des molécules biologiquement actives conçues pour être dirigées vers un site ou des composés de ciblage des particules. Les particules possèdent une demi-vie prolongée dans le sang par rapport à des particules ne contenant pas des fractions de polyalkylène glycol sur leurs surfaces.
CA002167920A 1993-07-23 1994-07-22 Nanoparticules et microparticules de copolymeres multisequences, hydrophiles-hydrophobes, non lineaires Abandoned CA2167920A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/096,370 US5543158A (en) 1993-07-23 1993-07-23 Biodegradable injectable nanoparticles
US096,370 1993-07-23
US210,677 1994-03-18
US08/210,677 US5565215A (en) 1993-07-23 1994-03-18 Biodegradable injectable particles for imaging
US08/265,440 US5578325A (en) 1993-07-23 1994-06-24 Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US265,440 1994-06-24

Publications (1)

Publication Number Publication Date
CA2167920A1 true CA2167920A1 (fr) 1995-02-02

Family

ID=27378175

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002167920A Abandoned CA2167920A1 (fr) 1993-07-23 1994-07-22 Nanoparticules et microparticules de copolymeres multisequences, hydrophiles-hydrophobes, non lineaires

Country Status (4)

Country Link
EP (1) EP0712421A1 (fr)
JP (1) JPH09504308A (fr)
CA (1) CA2167920A1 (fr)
WO (1) WO1995003356A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0965336A1 (fr) 1995-11-09 1999-12-22 Microbiological Research Authority ADN microencapsulé s'appliquant dans des procédés de thérapie génique
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
UA52701C2 (uk) 1996-10-11 2003-01-15 Басф Акцієнгезельшафт Твердий засіб захисту рослин та спосіб його одержання, спосіб боротьби з небажаним ростом рослин, спосіб боротьби з шкідливими грибами і тваринами-шкідниками та спосіб регулювання росту рослин
DE69735354T2 (de) 1996-10-28 2006-11-30 Amersham Health As Verbesserungen an oder in verbindung mit diagnostischen/therapeutischen verbindungen
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1998018498A2 (fr) * 1996-10-28 1998-05-07 Marsden, John, Christopher Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
US6610764B1 (en) 1997-05-12 2003-08-26 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
US6867248B1 (en) 1997-05-12 2005-03-15 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
FR2766195A1 (fr) * 1997-07-21 1999-01-22 Transgene Sa Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique
FR2766194A1 (fr) * 1997-07-21 1999-01-22 Transgene Sa Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique
US6828357B1 (en) 1997-07-31 2004-12-07 Metabolix, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
AR018528A1 (es) * 1997-12-12 2001-11-28 Expression Genetics Inc Mezcla polimerica biodegradable de micelas para transferencia genetica
AU751610B2 (en) 1997-12-22 2002-08-22 Tepha, Inc. Polyhydroxyalkanoate compositions having controlled degradation rates
ATE240121T1 (de) * 1998-01-29 2003-05-15 Kinerton Ltd Verfahren zur herstellung von absorbierbaren mikropartikeln
PT1053020E (pt) * 1998-01-29 2004-06-30 Poly Med Inc Microparticulas absorviveis
JPH11322948A (ja) * 1998-05-08 1999-11-26 Nof Corp 高分子微粒子およびその製造方法
CN1134479C (zh) 1998-12-15 2004-01-14 武田药品工业株式会社 制备聚合物的方法
JP4554084B2 (ja) 1999-03-04 2010-09-29 テファ， インコーポレイテッド 組織操作のための生体吸収性、生体適合性ポリマー
DK1163019T3 (da) 1999-03-25 2008-03-03 Metabolix Inc Medicinske indretninger og anvendelser af polyhydroxyalkanoatpolymere
AU5218500A (en) * 1999-06-22 2001-01-09 Aventis Research & Technologies Gmbh & Co. Kg Stable, radioactively marked nanoparticles, method for the production and utilization thereof
DE19930729A1 (de) * 1999-07-05 2001-01-11 Achim Goepferich Blockcopolymere zur Herstellung biomimetischer Oberflächen
IT1307263B1 (it) 1999-08-05 2001-10-30 Sorin Biomedica Cardio Spa Stent per angioplastica con azione antagonista della restenosi,relativo corredo e componenti.
FR2809112B1 (fr) * 2000-05-16 2004-05-07 Centre Nat Rech Scient Materiaux a base de polymeres biodegradables et son procede de preparation
JP2001324507A (ja) * 2000-05-18 2001-11-22 Nano Career Kk イムノナノスフェアーを含有する免疫測定用組成物
DE10025803A1 (de) * 2000-05-24 2001-12-20 Jms Co Ltd Polymeroberfläche mit biologisch aktiven Eigenschaften und Verfahren zu ihrer Herstellung
ES2188343B1 (es) * 2000-11-14 2004-11-16 Universidad De Zaragoza.O.T.R.I. Produccion de nanoparticulas magneticas monodispersas con un tamaño regulable empleando un polimero organico.
WO2003000237A2 (fr) * 2001-06-22 2003-01-03 Johns Hopkins University School Of Medicine Compositions polymeres biodegradables, compositions et leurs applications
AU2003300380B2 (en) 2002-12-30 2008-11-06 Nektar Therapeutics Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
EP2860292B1 (fr) 2003-05-08 2020-07-22 Tepha, Inc. Textiles et fibres médicaux en polyhydroxyalkanoate
JP4939936B2 (ja) * 2003-06-27 2012-05-30 株式會社アモーレパシフィック 生理活性成分を含有する自己集合性高分子ナノ粒子の製造方法、及び得られた自己集合性高分子ナノ粒子を含有する外用剤組成物
JP2005154514A (ja) * 2003-11-21 2005-06-16 Univ Waseda 機能性生分解性材料およびその製造方法
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
EP1768692B8 (fr) * 2004-07-01 2015-06-17 Yale University Materiaux polymères chargés de médicaments et ciblés à haute densité
ATE473021T1 (de) 2004-08-03 2010-07-15 Tepha Inc Nichtkräuselnde polyhydroxyalkanoatnähte
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US7811555B2 (en) * 2005-12-30 2010-10-12 Cordis Corporation Tri-branched biologically active copolymer
US8021689B2 (en) * 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
WO2007150030A2 (fr) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Synthèse microfluidique de nanoparticules organiques
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
WO2008109483A1 (fr) * 2007-03-02 2008-09-12 The Board Of Trustees Of The University Of Illinois Administration de médicament particulaire
WO2008124639A2 (fr) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Fractions de ciblage de poly (acide aminé)
EP1992371A1 (fr) * 2007-05-15 2008-11-19 Occlutech GmbH Matériaux en polymère radio-opaques biorésorbables et instrument d'occlusion ainsi fabriqué
CA2699887A1 (fr) * 2007-09-26 2009-04-02 Dsm Ip Assets B.V. Microparticules comprenant un polymere reticule
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
JP5629888B2 (ja) * 2009-08-19 2014-11-26 国立大学法人埼玉大学 糖鎖担持デンドリマーからなる標的選択的薬剤放出担体
US20120052097A1 (en) * 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
EP2825207B1 (fr) 2012-03-16 2020-08-19 The Johns Hopkins University Conjugués copolymère multi-blocs non linéaire-médicament pour l'administration de principes actifs
US9597385B2 (en) 2012-04-23 2017-03-21 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
KR102154880B1 (ko) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
AU2014216178B2 (en) 2013-02-15 2018-06-28 KALA BIO, Inc. Therapeutic compounds and uses thereof
EP2958895B1 (fr) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Composés thérapeutiques et leurs utilisations
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
EP3760223A1 (fr) 2013-04-03 2021-01-06 N-Fold Llc Nouvelles compositions de nanoparticules
CN105792925B (zh) * 2013-09-09 2018-03-09 微球实验公司 磁性颗粒的制造
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA2928658A1 (fr) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
EP3180040B1 (fr) 2014-08-15 2020-05-13 Tepha, Inc. Sutures auto-rétentives de poly-4-hydroxybutyrate et de copolymères de celui-ci
WO2016035806A1 (fr) * 2014-09-02 2016-03-10 株式会社Ｌｓｉメディエンス Microparticule polymère pour porter une substance physiologiquement active et procédé pour sa préparation
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
US9555155B2 (en) 2014-12-11 2017-01-31 Tepha, Inc. Methods of orienting multifilament yarn and monofilaments of poly-4-hydroxybutyrate and copolymers thereof
US20180311175A1 (en) * 2015-10-28 2018-11-01 University Of Maryland, College Park Multifunctional biodegradable carriers for drug delivery
CN105288631B (zh) * 2015-11-17 2018-10-30 杭州普施康生物科技有限公司 一种新型抗癌药物纳米制剂及其制备方法
CA3036065A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
CA3036340A1 (fr) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Formes cristallines de composes therapeutiques et leurs utilisations
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3614146B1 (fr) * 2017-04-21 2024-07-31 Haplopharma Inc. Procédé de détection d'aldostérone et de rénine
EP3614147B1 (fr) * 2017-04-21 2022-07-20 Haplopharma Inc. Procédé de détection d'une substance spécimen à l'aide de fines particules de polymère à plusieurs phases
WO2020072772A1 (fr) * 2018-10-03 2020-04-09 Fashion Chemicals Gmbh & Co. Kg Nouveaux esters d'acide polylactique couplés et esters d'acide polylactique couplés et compositions associées
CN112126052A (zh) * 2020-09-25 2020-12-25 亭创生物科技(上海)有限公司 一种官能化双嵌段共聚物及其制备方法和用途
CN114957588B (zh) * 2022-06-28 2023-10-24 瑞聚再生(厦门)医学科技有限公司 一种可生物吸收神经支架及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766165A (en) * 1966-08-17 1973-10-16 Pfizer Polysaccharides and their preparation
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
IL82834A (en) * 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
US5076807A (en) * 1989-07-31 1991-12-31 Ethicon, Inc. Random copolymers of p-dioxanone, lactide and/or glycolide as coating polymers for surgical filaments
CA2087125A1 (fr) * 1992-01-23 1993-07-24 Mridula Nair Micelles fixees chimiquement

Also Published As

Publication number Publication date
JPH09504308A (ja) 1997-04-28
EP0712421A1 (fr) 1996-05-22
WO1995003356A1 (fr) 1995-02-02

Similar Documents

Publication Publication Date Title
US6007845A (en) Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5578325A (en) Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
CA2167920A1 (fr) Nanoparticules et microparticules de copolymeres multisequences, hydrophiles-hydrophobes, non lineaires
US5543158A (en) Biodegradable injectable nanoparticles
Wei et al. Biodegradable poly (ɛ-caprolactone)–poly (ethylene glycol) copolymers as drug delivery system
Feng et al. Construction of functional aliphatic polycarbonates for biomedical applications
EP1856179B1 (fr) Copolymeres sequences de poly(ether-anhydride) fonctionnalises
CA2379672C (fr) Bloc copolymere d'oxyde de polyalkylene-poly(p-dioxanone) biodegradable soluble dans des solvants organiques et composition le contenant permettant de distribuer un medicament
CA2816977C (fr) Compositions et procedes visant a une reduction de la mucoadherence
Bai et al. Recent progress in dendrimer-based nanocarriers
KR100527291B1 (ko) 약물 전달체용 양이온기-함유 양친성 블록 공중합체 및그의 음이온성 약물과의 복합체
US20090012027A1 (en) Biodegradable polyphosphoramidates for controlled release of bioactive substances
US20050043481A1 (en) Material consisting of at least a biodegradable polymer and cyclodextrins
US7297347B2 (en) Polyanhydrides
JP2001515522A (ja) ポリマーキャリア
US10780175B2 (en) Polymer systems and their applications in diagnostics and drug delivery
Su et al. Enzymatic synthesis of PEGylated lactide-diester-diol copolyesters for highly efficient targeted anticancer drug delivery
Sasatsu et al. Preparation of a PLA–PEG block copolymer using a PLA derivative with a formyl terminal group and its application to nanoparticulate formulation
US6326021B1 (en) Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
Efthimiadou et al. New approach in synthesis, characterization and release study of pH-sensitive polymeric micelles, based on PLA-Lys-b-PEGm, conjugated with doxorubicin
Puri Novel functionalized polymers for nanoparticle formulations with anti cancer drugs
Kamble et al. Poly (lactic-co-glycolic acid)-polyethylene glycol copolymer for long-acting injectable: Synthesis, characterization, and in-vivo study
CN107303273A (zh) 一种增强肿瘤细胞摄取的pH敏感聚合物胶束组合物
Lanz Landázuri Modification of microbial polyacids for drug delivery systems

Legal Events

Date Code Title Description
FZDE Discontinued